China Independent Clinical Laboratory Industry Report, 2016-2020
  • Sep.2016
  • Hard Copy
  • USD $2,500
  • Pages:135
  • Single User License
    (PDF Unprintable)       
  • USD $2,300
  • Code: ZYM080
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,700
  • Hard Copy + Single User License
  • USD $2,700
      

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory market size has been growing radically in recent years, reaching about RMB6.5 billion with a year-on-year increase of 37.4% in 2015; it is expected to grow rapidly at a rate of 30%-40% over the next three to five years and report RMB29.2 billion in 2020. 

There are approximately200 independent clinical laboratory enterprises in China, mainly comprehensive diagnostic chains and special diagnostic enterprises. KingMed Diagnostics, Dian Diagnostics, ADICON Clinical Laboratories, and DaAn Health (invested by Da An Gene), which hold a combined market share of 70% and all adopt chain-based model of comprehensive diagnostic services. By the end of 2015, the four enterprises separately had 31, 26, 20 and 8 independent clinical laboratories. While expanding clinical laboratory services actively, all companies are deploying " laboratory +" industrial chain vigorously.

As a titan in China independent clinical laboratory industry, KingMed Diagnostics earned the revenue of RMB2.5 billion to RMB3 billion in 2015 with 40% market share. In the past two years, KingMed Diagnostics has been involved in production and sale of in vitro diagnostic products through acquisitions and independent R & D; moreover, it has made layout on "laboratory + Internet" services by acquiring GoHeath (Guangzhou Jinzhun), access to Tmall’s online pharmacies, etc..

Second to KingMed Diagnostics, Dian Diagnostics gained the revenue of RMB1.079 billion from independent clinical laboratory in 2015. In recent years, the company has implemented the strategy of horizontal expansion, vertical digging, technological innovation and industrial chain integration aggressively. It has arranged the " diagnosis +" ecosystem which refers to the expansion of other related services such as health management, judicial diagnostics, medicine CRO, cold chain logistics and mobile health with a focus on "diagnostic services + products". Since November 2015, the company has acquired Freda,Yuanding, ShengshiKehua, Faith Medical, Kingpe and many other high-quality IVD distributors for over RMB1 billion totally. In 2015, the company launched a new mode for chain expansion of physical examination services -- a health management center (Hangzhou Full-process International Health Medical Management Center Co., Ltd.) established with Hangzhou Jiebai, Baida Group. Meanwhile, Dian Diagnostics signed strategic cooperation agreements with The Johns Hopkins Hospital and AliHealth respectively to explore the "diagnosis + Internet" business mode energetically. At the beginning of 2016, Dian Diagnostics collaborated with Tigermed to set up a joint venture -- Shanghai Teddy Medical Institute Co., Ltd., marking the former’s foray into pharmaceutical CRO.

The third-ranked ADICON Clinical Laboratories which still enjoys superiority in East China has not realized the distribution of nationwide chain operation, but its special laboratory items have showed strong competitiveness. The company is not only authorized by the global pharmaceutical giant Roche to become "Roche’s Demonstration Laboratory in China", but also cooperates with Siemens Healthineers, Japan SRL, South Korea SCL, France Bio Mérieux, etc. in medical diagnostics.

Being bullish about the prospects of the Chinese independent clinical laboratory market, a number of small and medium Chinese independent clinical laboratory companies have drawn or plan to draw support fromthe capital market to further expand the clinical laboratory market. In 2014-mid-2016, Surexam Biotechnology, Shanghai Labway, Beijing Lepu, Shanghai Biotecan, Jiangsu Superbio, Beijing Lawke and other companies went public at NEW OTCBB in China. Wherein, Jiangsu Superbio witnessed the fastest revenue growth in clinical laboratory, namely the year-on-year surge of 161.0% in 2015; Shanghai Biotecan took the second place with the CAGR of 92.1% in 2013-2015. Shanghai Labway Clinical Laboraory obtained the clinical laboratory revenue of RMB127.8 million in 2015, but the revenue growth has slowed down due to the construction and expansion of laboratories in recent years.

China Independent Clinical Laboratory Industry Report, 2016-2020 highlights the followings:
20120114.gifPolicy environment, international market, development status, and competitive landscape of China’s independent clinical laboratory industry;
20120114.gifUpstream and downstream markets of China’s independent clinical laboratory industry and their impacts;
20120114.gifOperation, and independent clinical laboratory business of 19 relevant enterprises in China;
20120114.gifDevelopment outlook of China’s independent clinical laboratory industry in 2016-2020 and operational comparison among key players.

1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Industry Chain

2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.1.1 Access Policy
2.1.2 Industry Policy
2.2 International Market
2.2.1 Status Quo
2.2.2 Benchmarking Enterprises
2.3 Development
2.4 Competitive Landscape

3. Upstream and Downstream Markets of China Independent Clinical Laboratory Industry
3.1 Upstream Market
3.1.1 Status Quo
3.1.2 Competition Pattern
3.2 Downstream Market
3.2.1 Independent Clinical Laboratory Market Sees Huge Capacity
3.2.2 Healthcare Reform Boosts the Rapid Development of Independent Clinical Laboratory Market
3.2.3 Demand Diversification Promotes the Upgrading of Independent Clinical Laboratory Industry
3.2.4 Healthcare Demand Growth Propels the Independent Clinical Laboratory Forward Faster
3.2.5 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry

4. Key Players
4.1 KingMed Diagnostics
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Independent Clinical Laboratory
4.1.7 Client and Supplier
4.1.8 Forecast and Outlook
4.2 ADICON
4.2.1 Profile
4.2.2 Independent Clinical Laboratory
4.2.3 Development
4.3 Dian Diagnostics
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Independent Clinical Laboratory
4.3.7 Client and Supplier
4.3.8 Forecast and Outlook
4.4 DAAN Gene
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D and Investment
4.4.6 Independent Clinical Laboratory
4.4.7 Client and Supplier
4.4.8 Forecast and Outlook
4.5 Shanghai Labway Clinical Laboratory Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D and Investment
4.5.6 Independent Clinical Laboratory
4.5.7 Client and Supplier
4.5.8 Forecast and Outlook
4.6 NYMPHAVN Biotechnology
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D and Investment
4.6.6 Independent Clinical Laboratory
4.6.7 Forecast and Outlook
4.7 SurExam Bio-Tech Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D and Investment
4.7.6 Independent Clinical Laboratory
4.7.7 Client and Supplier
4.7.8 Forecast and Outlook
4.8 Ningbo Medicalsystem Biotechnology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D and Investment
4.8.6 Independent Clinical Laboratory
4.8.7 Client and Supplier
4.8.8 Forecast and Outlook
4.9 Beijing Lawke Health Laboratory Co., Ltd.
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 Forecast and Outlook
4.10 Beijing Lepu Gene Technology Co.,Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Gross Margin
4.10.4 Forecast and Outlook
4.11 Shanghai Biotecan Pharmaceuticals Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Independent Clinical Laboratory
4.11.6 Forecast and Outlook
4.12 Jiangsu Superbio Life Science Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 Client and Supplier
4.12.6 Forecast and Outlook
4.13 Other Enterprises
4.13.1 Kindstar Global
4.13.2 Xiamen Amoy Diagnostics Co., Ltd.
4.13.3 CapitalBio Corporation
4.13.4 Beijing Adinovo Technologies Co., Ltd.
4.13.5 Beijing Deyi Diagnostics Technology Co., Ltd.
4.13.6 IPE Biotechnology Co., Ltd.
4.13.7 Centre Testing International

5. Forecast and Outlook
5.1 Industry Development
5.2 Operation Comparison between Enterprises
5.2.1 Revenue
5.2.2 Gross Margin
Independent Clinical Laboratory Industry Chain
Comparison of Independent Clinical Laboratory Undertakers between China and USA
Policies Concerning Independent Clinical Laboratory Industry in China, 2010-2016
Market Share of Independent Clinical Laboratories in Major Countries
U.S. Independent Clinical Laboratory Market Share by Test Item
U.S. Clinical Laboratory Market Share by Demand Side
Revenue and Net Income of Quest, 2009-2016
Revenue of Quest Diagnostics by Business, 2014-2015
Major M&As of Quest Diagnostics, 2006-2015
Revenue and Operating Income of LabCorp, 2010-2016
Revenue Breakdown of LabCorp by Business, 2013-2016
Major M&As of LabCorp, 2007-2015
Market Scale of independent clinical laboratory industry in China,2013-2016
Revenue CAGR of Some Independent Clinical Laboratory Enterprises in China, 2012-2015
Market Share of Major Enterprises in China’s Independent Clinical Laboratory Industry, 2015
Basic Characteristics and Market Share of Major Independent Clinical Laboratory Enterprises in China, 2015
Development History of In Vitro Diagnostic Industry in China
Market Size of In Vitro Diagnostic Industry in China, 2009-2015
Market Structure of In Vitro Diagnostic Reagent Industry in China, 2015
Comparison of Diagnostic Instrument Varieties between Domestic and Foreign Enterprises
Competition Pattern of Diagnostic Reagent Industry in China
IVD Revenue and Market Share of Major Diagnostic Reagent Enterprises in China, 2013-2015
Business Revenue and Inspection Revenue of Public Hospitals in China, 2014
Per Capita Inspection Fees and % of Outpatient Expenses of Outpatients in Chinese Hospitals, 2010-2014
Per Capita Inspection Fees and % of Hospitalization Expenses of Inpatients in Chinese Hospitals, 2010-2014
Business Revenue and Inspection Revenue of Public Hospitals in China by Type of Visit, 2014
Medical Services of Health Agencies in China, 2012-2015
Number of Medical Institutions in China, 2012-2015
Health Expenditure and % of GDP in China, 1980-2015
Per Capita Health Expenditure and YoY Growth in China, 2006-2015
Revenue and Net Income of KingMed Diagnostics, 2012-2015
Revenue Breakdown of KingMed Diagnostics by Business, 2012-2015
Revenue Breakdown of KingMed Diagnostics by Region, 2012-2015
Gross Margin of KingMed Diagnostics by Business, 2012-2015
R&D Costs and % of Total Revenue of KingMed Diagnostics, 2012-2015
Proposed Fundraising & Investment Projects and Value of KingMed Diagnostics, 2016 
Distribution of Independent Clinical Laboratories of KingMed Diagnostics, as of June 2016 
Capacity and Output of KingMed Diagnostics (by Business), 2014-2015
Service Prices of KingMed Diagnostics (by Business), 2012-2015
Revenue of Dian Diagnostics from Top 5 Clients and % in Total Revenue, 2012-2015
Revenue of KingMed Diagnostics from Top 5 Clients and % of Total Revenue, 2014-2015
Procurement of KingMed Diagnostics from Top 5 Suppliers and % of Total Procurement, 2014-2015
Revenue and Net Income of KingMed Diagnostics, 2015-2020
Revenue and Net Income of Dian Diagnostics, 2010-2016
Revenue Breakdown of Dian Diagnostics by Product, 2010-2016
Revenue Breakdown of Dian Diagnostics by Region, 2009-2016
Gross Margin of Dian Diagnostics, 2010-2016
Gross Margin of Dian Diagnostics by Product, 2010-2015
R&D Costs and % of Total Revenue of Dian Diagnostics, 2010-2016
Dian Diagnostics’ Revenue from Independent Clinical Laboratory and YoY Growth, 2009-2016
Revenue of Dian Diagnostics’ Top 5 Clients and % in Total Revenue, 2011-2016
Revenue of Dian Diagnostics from Top 5 Clients and % of Total Revenue, 2015-2016
Procurement of Dian Diagnostics’ Top 5 Suppliers and % in Total Procurement, 2011-2016
Procurement of Dian Diagnostics’ Top 5 Suppliers and % in Total Procurement, 2015-2016 
Revenue and Net Income of Dian Diagnostics, 2015-2020E
Revenue and Net Income of Da An Gene, 2010-2016
Revenue Breakdown of Da An Gene by Business, 2010-2016
Revenue Breakdown of Da An Gene by Region, 2010-2016
Gross Margin of Da An Gene, 2010-2016
Gross Margin of Da An Gene by Business, 2010-2016
R&D Costs and % of Total Revenue of Da An Gene, 2011-2016
Main Assets and Business of Da An Gene
Industrial Chain Layout of Da An Gene
Medical Resources of Sun Yat-Sen University
Da An Gene’s Revenue from Independent Clinical Laboratory and YoY Growth, 2010-2016
Revenue of Da An Gene from Top 5 Clients and % in Total Revenue, 2014-2015
Top 5 Suppliers of Da An Gene, 2014-2015
Revenue and Net Income of Da An Gene, 2015-2020E
Revenue and Net Income of Shanghai Labway, 2013-2016
Revenue Breakdown of Shanghai Labway by Product, 2013-2016
Gross Margin of Shanghai Labway by Product, 2013-2016
R&D Costs and % of Medical Diagnosis Service’s revenue of Nymphavn Biotechnology, 2013-2016
Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2013-2016
Revenue of Shanghai Labway’s Top 5 Clients and % in Total Revenue, 2013-2015
Revenue of Shanghai Labway’s Top 5 Clients and % in Total Revenue, 2015
Procurement of Shanghai Labway’ Top 5 Suppliers and % in Total Procurement, 2013-2015
Procurement of Shanghai Labway’ Top 5 Suppliers and % in Total Procurement, 2015 
Revenue and Net Income of Nymphavn Biotechnology, 2009-2016
Revenue Breakdown of Nymphavn Biotechnology by Product, 2009-2016
Gross Margin of Nymphavn Biotechnology, 2009-2016
Gross Margin of Nymphavn Biotechnology by Product, 2009-2016
R&D Costs and % of Total Revenue of Nymphavn Biotechnology, 2011-2016
Revenue from and Gross Margin of Independent Clinical Laboratory Business of Nymphavn Biotechnology, 2009-2016
Revenue and Net Income of Nymphavn Biotechnology, 2015-2020E
Subsidiaries and Main Businesses of Surexam Biotechnology
Revenue and Net Income of Surexam Biotechnology, 2011-2016
Revenue Breakdown of Surexam Biotechnology by Business, 2011-2016
Gross Margin of Surexam Biotechnology, 2011-2016
Gross Margin of Surexam Biotechnology by Product, 2009-2016
R&D Costs and % of Total Revenue of Surexam Biotechnology, 2011-2016
Revenue from and Gross Margin of Independent Clinical Laboratory Business of Surexam Biotechnology, 2011-2016
Revenue of Surexam Biotechnology from Top 5 Clients and % of Total Revenue, 2015
Procurement of Surexam Biotechnology from Top 5 Suppliers and % of Total Procurement, 2015
Revenue and Net Income of Surexam Biotechnology, 2015-2020E
Revenue and Net Income of Medicalsystem Biotechnology, 2011-2016
Revenue Breakdown of Medicalsystem Biotechnology by Product, 2011-2016
Gross Margin of Medicalsystem Biotechnology by Product, 2011-2016
R&D Costs and % of Total Revenue of Medicalsystem Biotechnology, 2011-2016
Projects Proposed/Under Construction of Medicalsystem Biotechnology
Revenue from and Gross Margin of Independent Clinical Laboratory Business of Medicalsystem Biotechnology, 2011-2016
Revenue of Medicalsystem Biotechnology’ Top 5 Clients and % in Total Revenue, 2011-2016
Procurement of Medicalsystem Biotechnology’ Top 5 Suppliers and % in Total Procurement, 2011-2016
Revenue and Net Income of Medicalsystem Biotechnology, 2015-2020E
Revenue and Net Income of Beijing Lawke, 2013-2016
Revenue Breakdown of Beijing Lawke by Region, 2014-2016
Gross Margin of Beijing Lawke by Business, 2013-2016
Revenue and Net Income of Beijing Lawke, 2015-2020E
Revenue and Net Income of Lepu Gene, 2013-2016
Gross Margin of Lepu Gene,2013-2016
Revenue and Net Income of Lepu Gene, 2015-2020E
Revenue and Net Income of Biotecan,2013-2016
Revenue Breakdown of Shanghai Biotecan by Business 2014-2016
Gross Margin of Shanghai Biotecan, 2014-2016
Clinical Laboratory Revenue of Shanghai Biotecan and % of Total Revenue, 2013-2016 
Revenue and Net Income of Biotecan, 2015-2020E
Revenue and Net Income of Jiangsu Superbio, 2014-2015
Revenue Breakdown of JiangsuSuperbio by Business,2014-2015
Revenue Breakdown of S Jiangsu Superbio by Region,2014-2015
Gross Margin of Jiangsu Superb by business,2014-2015
Revenue of Jiangsu Superb from Top 5 Clients and % of Total Revenue, 2014-2015
Procurement of Jiangsu Superb from Top 5 Suppliers and % of Total Procurement, 2014-2015
Revenue and Net Income of Jiangsu Superbio, 2015-2020
Milestones of Kindstar Global
Some Strategic Partners of ADINOVO
Chinese Independent Clinical Laboratory Market Size and YoY Growth, 2014-2020E
Revenue of Major Independent Clinical Laboratory Enterprises in China, 2011-2016
Clinical Laboratory Revenue of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016
Gross Margin of Major Enterprises in Independent Clinical Laboratory Industry in China, 2012-2016
Gross Margin of Clinical Laboratory Business of Major Independent Clinical Laboratory Enterprises in China, 2012-2016

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统